Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, provides an overview of the antibody drug conjugates (ADCs) and their mechanism of action in delivering a cytotoxic payload directly and specifically to the tumor. There are currently many ADCs in clinical development in lung cancer demonstrating encouraging early clinical data. The question is whether ADCs can be combined with additional agents to safely enhance their clinical efficacy and which patients will benefit the most. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
